Roth E, Bruni C, Petelytska L, Becker MO, Dobrota R, Jordan S, Mihai C, Muraru S, Carreira PE, De Vries-Bouwstra J, Braun-Moscovici Y, Liakouli V, Moroncini G, Bergmann C, Mouthon L, Denton CP, De Santis M, Cauli A, Adler S, Bernardino V, Truchetet ME, Vonk M, Del Galdo F, Hoffmann-Vold AM, Distler Oet al.(2025) Gastroesophageal reflux disease is associated with a more severe interstitial lung disease in systemic sclerosis in the EUSTAR cohort Rheumatology (Oxford)(in press) DOI 10.1093/rheumatology/keaf016, PubMed 39775478
Allanore Y, Khanna D, Smith V, Aringer M, Hoffmann-Vold AM, Kuwana M, Merkel PA, Stock C, Sambevski S, Denton CP, SENSCIS Trial Investigators(2024) Effects of nintedanib in patients with limited cutaneous systemic sclerosis and interstitial lung disease Rheumatology (Oxford), 63(3), 639-647 DOI 10.1093/rheumatology/kead280, PubMed 37294870
Aringer M, Distler O, Hoffmann-Vold AM, Kuwana M, Prosch H, Volkmann ER(2024) Rationale for phosphodiesterase-4 inhibition as a treatment strategy for interstitial lung diseases associated with rheumatic diseases RMD Open, 10(4) DOI 10.1136/rmdopen-2024-004704, PubMed 39719300
